You are here: Industry Insights > HIV

News List

Moleculin Announces Antiviral Drug Candidates Demonstrate In Vitro Activity against HIV americanpharmaceuticalreview
October 10, 2020
Moleculin Biotech announced preliminary new findings from its research collaboration with the Rega Institute in Leuven, Belgium, that demonstrate its drug candidates, WP1096 and WP1097, are showing in vitro activity in a range of infectious diseases.
Experimental drug blocks COVID-19 viral entry into lung cells expresspharma
September 21, 2020
Researchers at NYU Grossman School of Medicine made changes to a free ACE2 molecule, and then fused one part of it to a piece of an antibody, an immune system protein, with the goal of strengthening its antiviral effect.
American Gene Technologies gets US FDA nod for Phase 1 clinical trial of potential HIV cure expresspharma
August 13, 2020
AGT’s Phase 1 trial will investigate the safety of AGT103-T, a single-dose, lentiviral vector-based gene therapy, and measure key biomarkers as well as explore surrogate markers of efficacy.
Final data on ViiV's cabotegravir show impressive HIV PrEP pharmatimes
July 09, 2020
ViiV's investigational, long-acting injectable cabotegravir was found to be 66% more effective than daily pills in preventing HIV-1 acquisition, according to final analysis of data from the HPTN 083 study.
Long-acting injectable HIV PrEP outperforms commercially available daily pill europeanpharmaceuticalreview
July 09, 2020
Extensive analysis of interim data finds patients given cabotegravir injection had a 66 percent lower incidence of HIV acquisition than those taking Truvada pills.
US FDA approves GSK’s HIV drug for patients with limited options expresspharma
July 06, 2020
The oral treatment from the company’s HIV unit, ViiV Healthcare, has been approved for adults whose HIV infection could not be successfully treated with other therapies due to resistance, intolerance or safety considerations.
FDA approves ViiV's novel HIV treatment Rukobia pharmatimes
July 03, 2020
The US Food and Drug Administration (FDA) has approved ViiV Healthcare's novel attachment inhibitor Rukobia (fostemsavir) expanding treatment options for HIV.
ViiV selects projects for HIV/COVID-19 response fund pharmatimes
July 02, 2020
ViiV Healthcare has announced that 109 projects from 26 countries are to get financial support from its Global HIV and COVID-19 Emergency Response Fund.
FDA approves ViiV Healthcare’s Tivicay to treat HIV in children pharmaceutical-technology
June 16, 2020
ViiV Healthcare has received approval from the US Food and Drug Administration (FDA) for Tivicay PD (dolutegravir) tablets, in combination with other antiretroviral agents, to treat children with human immunodeficiency virus type 1 (HIV-1) infection.
FDA approves drug to treat infants and children with HIV expresspharma
June 15, 2020
The safety and effectiveness of Tivicay and Tivicay PD were supported by a trial that included 75 HIV-1–infected infants, children and adolescents four weeks to less than 18 years old.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 24 25 Next page